Explore the vast range of titles available.

\"The field of autobiographical memory has made dramatic advances since the first collection of papers in the area was published in 1985. Now, over twenty-five years on, this book reviews and integrates the many theories, perspectives and approaches that have evolved over the last decades. A truly eminent collection of editors and contributors appraise the basic neural systems of autobiographical memory; its underlying cognitive structures and retrieval processes; how it develops in infancy and childhood, and then breaks down in aging; its social and cultural aspects; and its relation to personality and the self. Autobiographical memory has demonstrated a strong ability to establish clear empirical generalizations and shown its practical relevance by deepening our understanding of several clinical disorders - including the induction of false memories in the legal system. It has also become an important topic for brain studies and helped to enlarge our general understanding of the brain\"-- Provided by publisher.

I propose a model that places episodic, semantic, and other commonly studied forms of memory into the same conceptual space. The space is defined by three dimensions required for Tulving’s episodic and semantic memory. An implicit–explicit dimension contrasts both episodic and semantic memory with common forms of implicit memory. A self-reference dimension contrasts episodes that occurred to one person with semantic knowledge. A scene dimension contrasts episodes that occurred in specific contexts with context-free semantic information. The three dimensions are evaluated against existing behavioral and neural evidence to evaluate both the model and the concepts underlying the study of human memory. Unlike a hierarchy, which has properties specific to each category, the dimensions have properties that extend throughout the conceptual space. Thus, the properties apply to all forms of existing and yet-to-be-discovered memory within the space. Empty locations in the proposed space are filled with existing phenomena that lack a clear place in current theories of memory, including reports of episodic-like memories for events reported to but not witnessed by a person, fictional narrative accounts, déjà vu, and implicit components contributing to personality, the self, and autobiographical memory.

Mouschi the cat relates the experiences of Anne Frank and seven other people who hid in from Nazis in a secret annex over a factory in Amsterdam during the Holocaust. Includes facts about the Holocaust and about Anne Frank.

Ulcerative colitis (UC) is an idiopathic inflammatory disorder. These guidelines indicate the preferred approach to the management of adults with UC and represent the official practice recommendations of the American College of Gastroenterology. The scientific evidence for these guidelines was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process. In instances where the evidence was not appropriate for GRADE, but there was consensus of significant clinical merit, “key concept” statements were developed using expert consensus. These guidelines are meant to be broadly applicable and should be viewed as the preferred, but not only, approach to clinical scenarios.

ABSTRACT When democratic leaders renege on public threats to adversaries or commitments to allies, their domestic audiences can impose political sanctions: a mechanism known as democratic audience costs. Rationalist International Relations scholarship has extensively studied audience costs as an empirical phenomenon explaining crisis bargaining outcomes and alliance credibility, yet no normative account exists of the moral duties democratic audiences possess when deciding whether to sanction leaders for reneging on militarized threats or commitments. This article provides the first such normative account. I argue that democratic audience costs are morally significant because they rest on audiences’ morally grounded political rights and involve promise-breaking and trust-betrayal that harm both domestic publics and foreign allies. Building on these foundations, I propose a three-proposition normative framework: audiences have a pro tanto duty to sanction leaders who renege on public threats or commitments; this duty can be overridden when following through would create at least a moderate expected likelihood of basic human rights violations; and in such cases, audiences acquire an absolute duty to sanction leaders who fail to renege, provided this does not create even greater risks. I defend this account against objections concerning the epistemic capacities of mass publics, the moral relevance of direct versus indirect rights violations, and the justification for establishing non-reneging as the moral default. This framework bridges normative political theory and IR scholarship while providing practical guidance for democratic accountability in international disputes.

Continuum mechanics is a branch of physical mechanics that describes the macroscopic mechanical behavior of solid or fluid materials considered to be continuously distributed. It is fundamental to the fields of civil, mechanical, chemical and bioengineering. This time-tested text has been used for over 35 years to introduce junior and senior-level undergraduate engineering students, as well as graduate students, to the basic principles of continuum mechanics and their applications to real engineering problems. The text begins with a detailed presentation of the coordinate invariant quantity and the tensor, introduced as a linear transformation.

The management of patients with rheumatoid arthritis (RA) has rapidly evolved with the development of newer disease-modifying drugs and the recognition that long-term damage can be mitigated by an earlier and more-informed use of these medications. Historically, radiographs were the mainstay of imaging in RA patients, but radiographic joint narrowing and erosions are late and insensitive findings in the disease. MRI (with intravenous contrast agent) and ultrasound (with power Doppler interrogation) of the hands and wrists are able to demonstrate erosions earlier and with greater sensitivity than radiographs. More importantly, these imaging studies also depict synovitis and active soft-tissue inflammation, which represents a precursor to structural damage. Additionally, MRI can show inflammation within the bones (osteitis), which is proving to be the most important prognosticator of an aggressive disease course. Part I of this review discusses the imaging techniques, pitfalls, definitions, and comparative studies of MRI and ultrasound for identifying and quantifying erosions, synovitis, and osteitis. Part II will demonstrate how these imaging findings influence the clinical management of RA patients throughout their disease course, from presentation through clinical remission.

Extraintestinal manifestations (EIMs) are frequently observed in IBDs and contribute considerably to morbidity and mortality. They have long been considered a difficult to treat entity due to limited therapy options, but the increasing use of anti-tumour necrosis factors has dramatically changed the therapeutic approach to EIM in recent years. Newly emerging therapies such as JAK inhibitors and anti-interleukin 12/23 will further shape the available armamentarium. Clinicians dealing with EIMs in everyday IBD practice may be puzzled by the numerous available biological agents and small molecules, their efficacy for EIMs and their potential off-label indications. Current guidelines on EIMs in IBD do not include treatment algorithms to help practitioners in the treatment decision-making process. Herein, we summarise knowledge on emerging biological treatment options and small molecules for EIMs, highlight current research gaps, provide therapeutic algorithms for EIM management and shed light on future strategies in the context of IBD-related EIMs.

There is a great unmet need for new therapeutics with novel mechanisms of action for patients with Crohn's disease. The ADVANCE and MOTIVATE studies showed that intravenous risankizumab, a selective p19 anti-interleukin (IL)-23 antibody, was efficacious and well tolerated as induction therapy. Here, we report the efficacy and safety of subcutaneous risankizumab as maintenance therapy. FORTIFY is a phase 3, multicentre, randomised, double-blind, placebo-controlled, maintenance withdrawal study across 273 clinical centres in 44 countries across North and South America, Europe, Oceania, Africa, and the Asia-Pacific region that enrolled participants with clinical response to risankizumab in the ADVANCE or MOTIVATE induction studies. Patients in ADVANCE or MOTIVATE were aged 16–80 years with moderately to severely active Crohn's disease. Patients in the FORTIFY substudy 1 were randomly assigned again (1:1:1) to receive either subcutaneous risankizumab 180 mg, subcutaneous risankizumab 360 mg, or withdrawal from risankizumab to receive subcutaneous placebo (herein referred to as withdrawal [subcutaneous placebo]). Treatment was given every 8 weeks. Patients were stratified by induction dose, post-induction endoscopic response, and clinical remission status. Patients, investigators, and study personnel were masked to treatment assignments. Week 52 co-primary endpoints were clinical remission (Crohn's disease activity index [CDAI] in the US protocol, or stool frequency and abdominal pain score in the non-US protocol) and endoscopic response in patients who received at least one dose of study drug during the 52-week maintenance period. Safety was assessed in patients receiving at least one dose of study medication. This study is registered with ClinicalTrials.gov, NCT03105102. 712 patients were initially assessed and, between April 9, 2018, and April 24, 2020, 542 patients were randomly assigned to either the risankizumab 180 mg group (n=179), the risankizumab 360 mg group (n=179), or the placebo group (n=184). Greater clinical remission and endoscopic response rates were reached with 360 mg risankizumab versus placebo (CDAI clinical remission was reached in 74 (52%) of 141 patients vs 67 (41%) of 164 patients, adjusted difference 15% [95% CI 5–24]; stool frequency and abdominal pain score clinical remission was reached in 73 (52%) of 141 vs 65 (40%) of 164, adjusted difference 15% [5–25]; endoscopic response 66 (47%) of 141 patients vs 36 (22%) of 164 patients, adjusted difference 28% [19–37]). Higher rates of CDAI clinical remission and endoscopic response (but not stool frequency and abdominal pain score clinical remission [p=0·124]) were also reached with risankizumab 180 mg versus withdrawal (subcutaneous placebo; CDAI clinical remission reached in 87 [55%] of 157 patients, adjusted difference 15% [95% CI 5–24]; endoscopic response 74 [47%] of 157, adjusted difference 26% [17–35]). Results for more stringent endoscopic and composite endpoints and inflammatory biomarkers were consistent with a dose–response relationship. Maintenance treatment was well tolerated. Adverse event rates were similar among groups, and the most frequently reported adverse events in all treatment groups were worsening Crohn's disease, arthralgia, and headache. Subcutaneous risankizumab is a safe and efficacious treatment for maintenance of remission in patients with moderately to severely active Crohn's disease and offers a new therapeutic option for a broad range of patients by meeting endpoints that might change the future course of disease. AbbVie.

This study assessed the occurrence of indicators for suboptimal biologic therapy among ulcerative colitis (UC) and Crohn's disease (CD) patients over time in the United States (US). Data from a large US claims database (2005-2013) were used to retrospectively identify patients with diagnosed with either UC or CD who were new biologic users. Indicators of suboptimal biologic therapy included: dose escalation during the maintenance phase, discontinuation of the initial biologic, switch to another biologic within 90 days following the last day of supply of the initial biologic, augmentation with a non-biologic systemic therapy, UC- or CD-related surgery, UC- or CD-related urgent care, and development of fistula (for CD only). Kaplan-Meier analyses were used. A total of 1,699 UC and 4,569 CD patients were included. Among UC patients, 51.1% and 90.9% experienced ≥1 indicator of suboptimal biologic therapy within 6 months and 36 months of biologic therapy initiation, respectively. Among CD patients, 54.3% and 91.4% experienced ≥1 indicator of suboptimal biologic therapy within 6 and 36 months of biologic therapy initiation, respectively. For both UC and CD patients, the most frequent indicators of suboptimal biologic therapy were discontinuation, dose escalation and augmentation. In conclusion, this study found that the occurrence of suboptimal biologic therapy is common among patients with UC and CD, with approximately 90% of patients experiencing at least one indicator of suboptimal biologic therapy within 36 months of biologic treatment initiation.